Allscripts Healthcare Solutions, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2012. For the quarter, the company reported total revenue of $364.7 million compared to $335.3 million a year ago. Income from operations was $13 million compared to $24.5 million a year ago. Income before income taxes was $9.5 million compared to $16.9 million a year ago. Net income was $5.8 million or $0.03 per basic and diluted share compared to $12.6 million or $0.07 per basic and diluted share a year ago. Net cash provided by operating activities was $74.6 million compared to $66.9 million a year ago. Capital expenditures were $19.4 million compared to $11.8 million a year ago. Total non-GAAP revenue was $365.5 million compared to $346.1 million a year ago. Total non-GAAP operating income was $40.9 million compared to $72.1 million a year ago. Non-GAAP net income was $23.5 million or $0.12 per diluted share compared to $40.6 million or $0.21 per diluted share a year ago. The company also announced that Bill Davis, Chief Financial Officer, has decided to leave the company, effective May 18, 2012, to pursue another opportunity with a private company outside of the healthcare industry. Dave Morgan, Senior Vice President Finance, will become the Interim Chief Financial Officer while the company conducts a formal search for Mr. Davis's successor. Mr. Morgan previously served as SVP Finance and Chief Accounting Officer of Eclipsys. The company also announced that Phil Pead's service as Chairman of the Board, director and officer of the company terminated on April 25, 2012. Prior to this action, the Board engaged in extensive deliberations regarding the leadership of the company. Following the deliberations, those who concurred with the consensus regarding such leadership expressed their intention to continue as directors, and those who did not concur (Catherine M. Burzik, Eugene V. Fife and Edward A. Kangas) informed the company that they have resigned as directors. The company revised earnings guidance for the year of 2012. The company now expects non-GAAP revenue in the range of $1,480.0 million to $1,520.0 million, non-GAAP operating margin in the range of 16.0% to 17.0%, effective tax rate in the range of 36.5% to 37.0% and non-GAAP diluted EPS in the range of $0.74 to $0.80.